TRAF3IP2 and cancer: It is, therefore, why the effector cells activated by cytokines are considered an ideal candidate for cancer immunotherapy, including LAK cells, activated NK cells, dendritic cells, activated lymphocytes, TILs, and CIKs—all exhibiting antitumor activity in various contexts.